Access to Cancer Drugs in Canada

Lung cancer, because of the multiple subtypes now identifiable and because of the myriad of new and effective therapies, provides fertile ground to highlight issues related to oncology drug access in Canada [...].

[1]  G. Batist,et al.  Access Denied? The Unintended Consequences of Pending Drug Pricing Rules , 2022, Current oncology.

[2]  S. Snow,et al.  Not All Canadian Cancer Patients Are Equal—Disparities in Public Cancer Drug Funding across Canada , 2022, Current oncology.

[3]  A. Chambers,et al.  Is It Time to Commit to a Process to Re-Evaluate Oncology Drugs? A Descriptive Analysis of Systemic Therapies for Solid Tumour Indications Reviewed in Canada from 2017 to 2021 , 2022, Current oncology.

[4]  L. Binder,et al.  Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations , 2022, Current oncology.

[5]  Eva G. Villalba,et al.  Closing the Gaps to Timely Patient Access: Perspectives on Conditional Funding Models , 2022, Current oncology.

[6]  P. Wheatley‐Price,et al.  The Pathway for New Cancer Drug Access in Canada , 2022, Current oncology.

[7]  D. Regier,et al.  FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment , 2022, Current oncology.

[8]  John J. Shin,et al.  Determinants of the Cancer Drug Funding Process in Canada , 2019, Current oncology.

[9]  S. Gill,et al.  Current Attitudes toward Unfunded Cancer Therapies among Canadian Medical Oncologists , 2021, Current oncology.

[10]  A. Denburg,et al.  Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise , 2021, Current oncology.

[11]  A. Denburg,et al.  Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group , 2021, Current oncology.

[12]  C. Mitton,et al.  Describing Sources of Uncertainty in Cancer Drug Formulary Priority Setting across Canada , 2021, Current oncology.

[13]  A. Mansfield,et al.  First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial , 2021, The Lancet.

[14]  Jie Yang,et al.  Tepotinib in Non‐Small Cell Lung Cancer with MET Exon 14‐Skipping Mutations or MET Amplification: a Phase 2 Trial in Progress: OA06 , 2018, The New England journal of medicine.